BioSpace News Archive

Resolve Therapeutics, pioneering first-in-class, targeted, safe therapies for underserved autoimmune diseases, announced completion of enrollment in its Phase 2a study of RSLV-132 for the treatment of Systemic Lupus Erythematosus (SLE; “lupus”).

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2019 financial results after the market close on Wednesday, August 7, 2019.

Spectrum Pharmaceuticals, Inc., announced that it is further expanding its poziotinib clinical program by adding three new cohorts in its cornerstone poziotinib clinical trial, ZENITH20.

Amneal Pharmaceuticals, Inc., announced that it has received approval for, and launched, its generic version of Lyrica® (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg.

MED-EL USA announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s cochlear implant system for single-sided deafness (SSD) and asymmetric hearing loss (AHL).

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that the final results of Progenics’ 2019 Annual Meeting of Stockholders

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced initial results of its Pilot Study of the BioLexa Platform’s application on diabetic skin ulcers.

DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Gilead Sciences, Inc. granting Gilead the exclusive worldwide rights to develop and commercialize a long-acting injectable HIV product utilizing DURECT’s SABER® technology

Wireless Cardiac Pacing System being evaluated in global clinical study for Heart Failure Patients

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the inclusion of overall survival (OS) data from the Phase III PACIFIC trial in an update to the IMFINZI®